

## Astra's Tackle disappoints



[Elizabeth Cairns](#)

Astrazeneca is already seeking authorisation of its antibody combo AZD7442 for the prevention of Covid-19. Today's topline data from [the Tackle study](#) show the project to have utility in the outpatient treatment setting, too, halving the risk of severe infection or death when given within seven days of symptom onset. In a prespecified subset who received the treatment within five days of symptom onset, AZD7442 cut this risk by 67% versus placebo. But there are a couple of reasons for caution. Most obviously, Merck & Co [recently showed a similar level of efficacy](#) in the same setting with molnupiravir, which has the vast advantage of being oral. And several other antibodies and antibody combos are already authorised for the treatment of non-hospitalised patients, with notably better headline efficacy than AZD7442. Perhaps '7442 has a bit of an edge over these in that it is long-acting, and is delivered intramuscularly rather than needing to be infused – but molnupiravir clearly still wins on convenience. Forecast sales for '7442 are far behind the blockbuster numbers the sellside has pencilled in for many of these treatments, and this situation seems unlikely to change on the back of the Tackle data.


### Selected Covid-19 MABs and antivirals for outpatient treatment

Project	Company	Trial	Cut in risk of hospitalisation/ death vs pbo	EUA for outpatient treatment?
AZD7442	Astrazeneca	<a href="#">Tackle</a>	50%*, "statistically significant"	No
Molnupiravir	Merck & Co	<a href="#">Move-Out</a>	50%, $p=0.0012$	Filed
BRII-196/BRII-198	Brii Biosciences	<a href="#">Activ-2</a>	78%, $p<0.00001$	Filed
Ronapreve (casirivimab + imdevimab)	Regeneron/Roche	<a href="#">COV-20678</a>	70%, $p=0.0024$	Yes
Bamlanivimab + etesevimab	Lilly	<a href="#">Blaze-1</a>	70%, $p= 0.0004$	Yes
Sotrovimab (VIR-7831)	Glaxosmithkline/ Vir	<a href="#">Comet-Ice</a>	79%, $p<0.001$	Yes

\*Reduction in risk of severe Covid-19 or death. Source: company releases.

# Treating Covid-19 outpatients

## Selected Covid-19 Mabs and antivirals



Source: Evaluate Pharma, except ^Berenberg and ^^SVB Leerink.

[More from Evaluate Vantage](#)

Evaluate HQ  
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas  
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC  
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2021 Evaluate Ltd.